Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more
Psyence Biomedical Ltd. Common Shares (PBM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.060x
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has a cash flow conversion efficiency ratio of 0.060x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00) by net assets ($-10.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Psyence Biomedical Ltd. Common Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Psyence Biomedical Ltd. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CARACAL GOLD PLC LS-001
F:6IK
|
N/A |
|
CTS EVENTIM
BE:EVD
|
-0.117x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
RENCO HOLDINGS GRP HD-10
F:TP7
|
N/A |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
CORP. FIN. ALBA - Dusseldorf Stock Exchang
DU:CSV
|
N/A |
|
O REILLY AUTO - Dusseldorf Stock Exchang
DU:OM6
|
-0.599x |
|
Labrador Technologies Inc
V:LTX
|
0.042x |
Annual Cash Flow Conversion Efficiency for Psyence Biomedical Ltd. Common Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Psyence Biomedical Ltd. Common Shares from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.72 Million | $-3.73 Million | -0.556x | -306.95% |
| 2024-03-31 | $-10.97 Million | $-2.95 Million | 0.268x | +12739.31% |
| 2023-03-31 | $244.66 Million | $-519.60K | -0.002x | +63.52% |
| 2022-03-31 | $239.84 Million | $-1.40 Million | -0.006x | -- |